Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Products under Development by Stage of Development | 7 | 1 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Products under Development by Therapy Area | 8 | 1 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Products under Development by Indication | 9 | 1 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Products under Development by Companies | 12 | 2 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Therapeutics Assessment | 14 | 4 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 1 |
| Assessment by Molecule Type | 17 | 1 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Companies Involved in Therapeutics Development | 18 | 5 |
| Basilea Pharmaceutica AG | 18 | 1 |
| Eli Lilly and Company | 19 | 1 |
| Millennium Pharmaceuticals, Inc. | 20 | 1 |
| Novartis AG | 21 | 1 |
| Redx Pharma Plc | 22 | 1 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Drug Profiles | 23 | 9 |
| BAL-3833 Drug Profile | 23 | 2 |
| LXH-254 Drug Profile | 25 | 1 |
| LY-3009120 Drug Profile | 26 | 2 |
| Small Molecules to Inhibit Pan-RAF Kinase for Oncology Drug Profile | 28 | 1 |
| Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer Drug Profile | 29 | 1 |
| TAK-580 Drug Profile | 30 | 2 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Dormant Projects | 32 | 1 |
| Serine/Threonine-Protein Kinase A-Raf (A-Raf Kinase or Proto-Oncogene A-Raf or Proto-Oncogene Pks or EC 2.7.11.1) Featured News &Press Releases | 33 | 5 |
| Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting | 33 | 1 |
| Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting | 33 | 1 |
| Apr 22, 2015: Deciphera Pharmaceuticals Presents Data Highlighting pan-RAF inhibitor Cetuximab including Proprietary and Partnered Programs at AACR 2015 Annual Meeting | 34 | 1 |
| Apr 20, 2015: Lilly Releases Early-Stage Pipeline Data On LY3009120 at AACR Annual Meeting 2015 | 34 | 1 |
| Apr 07, 2014: Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 | 35 | 1 |
| Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors | 36 | 1 |
| Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec | 36 | 1 |
| Sep 07, 2004: Biogen Idec And Sunesis Form Collaboration To Discover And Develop Multiple Small Molecule Oncology Products | 36 | 2 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |